Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0B1GE
|
|||
| Drug Name |
KB103
|
|||
| Indication | Dystrophic epidermolysis bullosa [ICD-11: EC32; ICD-10: Q81.2] | Phase 2 | [1] | |
| Company |
Krystal Biotech Pittsburgh, PA
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03536143) Topical Beremagene Geperpavec (KB103) Gene Therapy to Restore Functional Collagen VII for the Treatment of Dystrophic Epidermolysis Bullosa (GEM-1). U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.